The acute effect of orlistat on endothelial function in young obese women

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 4, 2003, Pages 111-117

  Sekuri, C ^a,c   Tavli, T ^a   Avsar, A ^b   Sozcuer, H ^b   Uyanik, B S ^a   Ari, Z ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b State Mental Hospital   (Turkey)

^c NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HUMAN; HYPEREMIA; OBESITY; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BODY MASS INDEX; BRACHIAL ARTERY; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; LACTONES; OBESITY; TRIGLYCERIDES; VASODILATION;

EID: 3042601833     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Foreyt J., Goodrick L. The ultimate triumph of obesity. Lancet, 346, 134, 1995.
2. Higgins M., Kannel W., Garrison R., Pinsky J., Strokes J. Hazards of obesity. The Framingham experience. Acta Med. Scand., 723, 23, 1988.
3. Must A., Jaques P.F., Dallal G.E., Bajema C.J., Dietz W. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard growth study of 1922-1935. N. Engl. J. Med., 327, 1350, 1992.
4. Pi-Sunyer F.X. Medical hazards of obesity. Ann. Intern. Med., 119, 655, 1993.
5. Goldstein D.J., Parvin J.H. Long-term weight loss: The effect of pharmacologic agents. Am. J. Clin. Nutr., 60, 647, 1994.
6. Hauptman J.B., Jeunet F.S., Hartman D. Initial studies in humans with the novel gastrointestinal lipase inhibitor RO 18-0647 (tetrahydrolipstatin). Am. J. Clin. Nutr., 55, S309, 1992.
7. Sharma A.M., Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J. Hypertens., 20, 1873, 2002.
8. Heymsfield S.B., Segal K.R., Hauptman J., et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch. Intern. Med., 160, 1321, 2000.
9. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA, 281, 235, 1999.
10. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide accounts for the biologic activity of endothelium-dependent relaxing factor Nature, 327, 524, 1987.
11. Ludmer P.L., Selwyn A.P., Shook T.L. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med., 315, 1046, 1986.
12. Dzau V.J., Burt D.W., Pratt R.E. Monocular biology to the renin-angiotensin system. Am. J. Physiol., 255, 563, 1988.
13. Lean M.E., James W.P. Prescription of diabetic diets in the 1980s. Lancet, 1, 723, 1986.
14. Schofield W.N. Predicting basal metabolic rate, new standards and review of previous work. Hum. Nutr. Clin. Nutr., 39, 5, 1985.
15. Drent M.L., Larsson I., William-Olsson T., et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int. J. Obesity, 19, 221, 1995.
16. Sjöström L., Rissanen A., Andersen T., et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167, 1998.
17. Joseph L.J.O., Ryan A.S., Sorkin J., et al. Body fat distribution and flow-mediated endothelium-dependent vasodilation in older men. Int. J. Obesity, 26, 663, 2002.
18. Hashimoto M., Akishita M., Eto M., et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int. J. Obes. Relat. Metab. Disord., 22, 477, 1998.
19. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance. J. Clin. Invest., 97, 2601, 1996.
20. Arcaro G., Zamboni M., Rossi L., et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int. J. Obes. Relat. Metab. Disord., 23, 936, 1999.
21. Baldeweg S.E., Pink A.M., Yudkin J.S., Coppack S.W. The relationship between obesity vascular reactivity and endothelial dysfunction in subjects with non-insulin dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord., 24, S134, 2000.
22. Perticone F., Ceravolo R., Candigliota M., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: Protective effect of vitamin C. Diabetes, 50, 159, 2001.
23. Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol. Rev., 74, 761, 1994.
24. Flavahan N.A., Vanhoutte P.M. Endothelial cell signaling and endothelial dysfunction. Am. J. Hypertens., 8, 28S, 1995.
25. Peiris A.N., Sothmann M.S., Hoffmann R.G., et al. Adiposity fat distribution, and cardiovascular risk. Ann. Intern. Med., 110, 867, 1989.
26. Cosentino F., Luscher T.F. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmac., 32 (Suppl 3), S54, 1998.
27. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care, 21, 1288, 1998.